Purpose To investigate the effects of Merogel coverage on ostial patency in endonasal endoscopic dacryocystorhinostomy (EES-DCR) for primary chronic dacryocystitis (PCD). Methods In all, 260 patients with unilateral PCD were randomized into two groups: the Merogel group and the control group. All patients underwent EES-DCR. The Merogel group received Merogel covering the wound 1-2 mm around the ostium and the control group received no treatment. Patients were followed up for 9 months. The mucosal epithelialization of the wound, the proliferation of fibrosis tissue, and the success rate of ostial patency were compared. Results Our study included 112 patients in the Merogel group and 115 patients in the control group. At the 2-week review, intact mucosal epithelium lined the ostia in 96 Merogel patients compared with 80 control patients (ITT analysis: v 2 ¼ 4.502, P ¼ 0.034). At the 9-month review, scars were present in 18 patients in the Merogel group compared with 39 patients in the control group (ITT analysis: v 2 ¼ 9.909, P ¼ 0.002, ITT analysis). No differences were observed in the granulation formation between the two groups. The success rate of ostial patency reached 94.6% (106/112) in the Merogel group compared with 80% (92/115) in the control group (ITT analysis:
Introduction
Recently, the endonasal endoscopic approach for dacryocystorhinostomy (EES-DCR) has become increasingly popular over the external dacryocystorhinostomy (Ex-DCR) approach. The success rate for EES-DCR, however, varies markedly from 54 to 96%. [1] [2] [3] [4] [5] [6] [7] [8] Numerous modifications have been developed to promote ostial patency, ranging from various methods of producing the nasal mucosal and/or lacrimal sac flaps, 2, 4, [9] [10] [11] [12] varying the size of the bony ostium, 4, [12] [13] [14] lacrimal sac incision, 15 to stenting. 16, 17 Nevertheless, ostial closure or obstruction still occurs, mostly due to excessive scars/synechia or granulation formation at the ostium. 3, 5, 6, 8, 9, [18] [19] [20] Some authors advocate the use of mitomycin C (MMC) intraoperatively to reduce fibrosis formation, [21] [22] [23] [24] [25] [26] although granulation tissue has been reported to form around the ostia following MMC application during EES-DCR. 27, 28 Hyaluronan is a ubiquitous polysaccharide component of the extracellular matrix. Both hyaluronan and its derivatives have been reported to reduce scarring and to promote wound healing in naso-sinal surgery. [29] [30] [31] Merogel (Medtronic Xomed, Jacksonville, FL, USA) is an esterified derivative of hyaluronan that appears to have a longer duration than hyaluronan and can be easily used in a non-woven sponge preparation. Merogel has been used as an antiadhesive packing agent with good effect to stimulate mucosal epithelial healing in functional endoscopic sinus surgery (FESS), [29] [30] [31] middle ear surgery, 32, 33 and tympanic membrane perforation repair surgery. 34 However, a number of studies have disputed the role of Merogel in mucosal epithelium recovery. [35] [36] [37] [38] Our study aimed to investigate whether Merogel coverage stimulates wound mucosal regeneration and its epithelialization around the ostia to improve long-term ostial patency in EES-DCR.
Materials and methods
This study was conducted at the Eye Hospital of Wenzhou Medical College between October 2006 and February 2010. Ethical approval was obtained from the Institutional Review Board and informed consent was obtained from all subjects, in accordance to the tenets of the declaration of Helsinki. The diagnosis of primary chronic dacryocystitis (PCD) was made on the basis of a history of epiphora with purulent discharge and regurgitation on nasolacrimal irrigation. All consecutive patients with unilateral PCD were included in the study. We excluded patients with acute dacryocystitis, a previous history of physical scars, previous lacrimal surgery, eyelid malposition including ectropion or entropion, and previous facial fractures or nasal diseases, such as polyps and chronic rhinosinusitis. Patients with isolated nasal septum deviation were not excluded. All patients underwent non-laser EES-DCR, which was performed by a single surgeon (WW). Before surgery, all patients were randomized by an independent member of the staff into two groups. The first group received Merogel at the end of the procedure, which covered the wound 1-2 mm around the ostium (the Merogel group), and the second group received nothing at the end of the routine EES-DCR (control group).
Surgical technique of non-laser EES-DCR
The non-laser EES-DCR was performed mainly as described by Tsirbas et al 4, 10 and Wu et al. 39 A mixture of 2 ml of 2% lidocaine and epinephrine (1 : 1 00 000) was injected into the lateral nasal wall in addition to an external anterior ethmoidal nerve block and an infraorbital nerve block. Under direct visualization with a 451 4-mm endonasal endoscope (Karl Storz, Tuttlingen, Germany), the lateral nasal mucosa was incised in the area of the lacrimal sac fossa and removed. An osteotomy (8 mm Â 10 mm in size) was created using an angled (151) coarse diamond burr attached to a microdebrider (XPS3000, Medtronic Xomed, Minneapolis, MN, USA) and/or a Hajek-Koffler forward-biting punch. Further, the lacrimal sac was tented using a probe through the superior canaliculus and incised vertically with a sickle knife to create a large posterior lacrimal sac flap. The flap was then flattened on the lateral nasal mucosal wall; this was the final step in the procedure for the control group. In the Merogel group, two pieces of Merogel were stretched to cover the flattened posterior lacrimal sac flap and the wound surface 1-2 mm around the ostium (Figures 1a and b) .
Postoperative care and follow-up
All patients were hospitalized for the surgery and received oral antibiotics for 5-7 days. Patients were discharged on a monthly prescription of a topical mixture of antibiotic and steroid eye drops four times daily (Maxitrol, Alcon Laboratories, Fort Worth, TX, USA), and an intranasal steroid spray three times daily (Rhinocort Aqua, AstraZeneca, Wilmington, DE, USA). A nasal endoscopic examination was performed at day 3, following surgery on all patients with careful removal of blood clots/debris obstructing the ostial site. This was repeated every 2-3 days over the next 2 weeks. Followup reviews were weekly for 2 weeks, then monthly for 2 months, and finally every 2-3 months for the next 9 months. At each review, regular nasal endoscopic examinations were carried out to assess the wound healing, with specific reference to the status of epithelial mucosa and the presence of scars and granulation tissue within 1-2 mm of the ostium, as described by Berlucchi et al 29 and Xu et al. 30 Symptoms of epiphora and purulent discharge were recorded and nasolacrimal irrigation was performed by an independent member of the staff.
The patent ostium was defined as an ostium that was freely flowing with no regurgitation on nasolacrimal irrigation, and was lined by 1-2 mm of healthy epithelized mucosa. Successful outcome was defined subjectively and objectively by a patent ostium in the absence of epiphora and purulent discharge at the 9-month review.
Statistical analyses
Statistical analyses were performed with SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Group means of primary data of the patients were compared with an independent sample t-test. Success rates of the freely flowing lacrimal reconstruction, ostial patency, ostial epithelization, and ostial fibrosis at the 9-month review 
Results
We randomly assigned 260 patients with unilateral PCD into two groups. In all, 18 patients in the Merogel group were excluded for the following reasons: 11 patients had no Merogel present over the ostial site at the first week of surgery, as detected by the first and second endonasal examination and 7 patients failed to complete the follow-up. In all, 15 patients in the control group were excluded, 3 patients had complicated heavy nasal bleeding within the first week following surgery, and 12 patients failed to complete the follow-up. Therefore, we included 112 patients in the Merogel group and 115 patients in the control group. There were no significant differences between the groups for patient age, gender, and history of symptoms (Table 1 ). In all, 13 patients in the Merogel group underwent nasal septoplasty compared with 17 patients in the control group for significant septal deviation.
We found that the Merogel was mostly absorbed within 2 weeks following surgery (Figures 2a and b) . At the 2-week review, all ostia remained patent for both groups. We found that 96 patients (85.7%) in the Merogel group had a healed ostium with a lining of intact epithelial mucosa compared with 80 patients (69.6%) in the control group (PP analysis: w 2 ¼ 8.495, P ¼ 0.004; ITT analysis: w 2 ¼ 4.502, P ¼ 0.034; Table 2 ). At the 9-month review, healthy epithelial mucosa lined the ostia in 94 patients (83.9%) in the Merogel group (Figure 2c) (Table 2) . Table 3 compares the scarring and the granulation formation between the two groups. At the 9-month review, scars were present in 18 Merogel patients compared with 39 control patients (PP analysis: w 2 ¼ 9.605, P ¼ 0.002; ITT analysis: w 2 ¼ 9.909, P ¼ 0.002). We observed no significant difference in granulation formation between the two groups.
Four patients had a failed outcome compared with 21 control patients (P ¼ 0.043; Figures 3a and b) . Granulation tissue resulting in partial/complete ostial obstruction occurred in four of those failures, two patients from each group (P ¼ 0.565; Figures 3c and d; Table 3 ). The remaining failed patients did not have visible ostial closure/stenosis, but had variable degrees of fibrosis proliferation present within 1-2 mm of the ostia; Figures 4a-d) .
Discussion
Silicone stenting 16, 17 and the application of mitomycin C [21] [22] [23] [24] [25] [26] are the most commonly used methods to maintain ostial patency in EES-DCR surgery. However, limitations have been reported for both of them, including the potential of silicone intubation to induce an [18] [19] [20] and the inhibitory effect of MMC on fibroblasts, which potentially limits the regeneration of healthy epithelium. 27, 28 Therefore, the ideal agent should promote healthy re-epithelialization without excessive scarring, to ensure ostial patency in DCR. Our study showed that, at the 2-week review, 85.7% of the patients (96/112) in the Merogel group had epithelial mucosa lining the ostia, which was higher than that in the control group (69.6%, 80/115). At the 9-month review, the success rate of ostial patency reached 93.4% (106/112) in the Merogel group, as opposed to the control group (82.6%, 92/115). We observed that the rate of scar formation was lower in the Merogel group, with a lower incidence of ostial failure than in the control group. These results suggest that Merogel coverage can significantly improve the success rate of ostial patency for EES-DCR by stimulating wound healing and mucosa epithelialization and by preventing the formation of fibrotic tissue around the ostia. This is consistent with previous studies. [29] [30] [31] Berlucchi et al 29 found that the patients packed with Merogel had less nasal adhesions at both 4 and 12 weeks, compared with the traditional non-resorbable packs during FESS. They also reported an improvement in re-epithelialization with reduced granulation tissue in the Merogel group, which was supported by Xu et al. 30 37 suggested that Merogel tended to increase reactive fibrosis and impair mucosal healing when used as a packing agent in rabbit maxillary sinus wounds. We propose that these limited effects observed with Merogel may be explained by the large mucosal areas denuded during their procedure and that the mechanisms of wound healing and mucosa epithelialization is different between FESS for chronic rhinosinusitis and EES-DCR without rhinosinusitis.
Traditionally, it was critical during EES-DCR to create one nasal sac flap and one lacrimal sac flap and to appose them closely. 2, 8, [9] [10] [11] 14 Our technique involves removal of the nasal mucosa flap and the creation of a large C-shaped lacrimal sac flap that is laid flat posteriorly to cover the lateral nasal mucosal wall, as described by Wu et al. 39 We appose the lacrimal sac flap border with the nasal mucosal wall. At the 2-week review, we observed that more patients in the Merogel group had healthy epithelial-lined ostia, especially in the areas between the lacrimal sac and the lateral nasal mucosa wall, than the control group. This suggests that Merogel has a role in promoting mucosal epithelial regeneration, which we consider a key factor for maintaining ostial patency. It also offers additional benefit as a physical packing material in maintaining opposition of the flaps. This was particularly apparent in patients with small lacrimal sacs, at which the creation of a large posterior lacrimal flap was difficult.
Our study has demonstrated that adjunctive use of Merogel may enhance the success outcomes in EES-DCR for PCD. The mechanisms for this enhancement may include the following: (1) Merogel helps promotion of early re-epithelialization of the ostium; (2) it inhibits the fibrotic tissues at the ostium; and (3) it serves as a physical packing barrier for apposition of lacrimal sac and nasal mucosa flaps.
K Though numerous modifications, including surgical techniques, silicone intubation, and intraoperative application of mitomycin C, have been used to promote success rate of endonasal endoscopic dacryocystorhinostomy (EES-DCR), some patients have still failed in ostial patency because of ostial stenosis or closure resulted from excessive scars and/or granulation tissue formation.
What this study adds
K Our study has demonstrated that adjunctive use of Merogel can significantly improve the success rate of ostial patency for EES-DCR by stimulating wound healing and mucosa epithelialization and by preventing the formation of fibrotic tissue around the ostia.
